Thermo Fisher Scientific 1Q Revenue Tops Estimates, Raises 2024 Outlook
By Denny Jacob
Thermo Fisher Scientific posted better-than-expected revenue in its latest quarter, leading the company to raise its outlook for 2024.
The scientific-equipment company logged net income of $1.33 billion, or $3.46 a share, for the first quarter ended March 30, up from $1.29 billion, or $3.32 a share, a year earlier. Adjusted earnings were $5.11 a share, above analysts' estimates of $4.71 a share.
Revenue edged down 3% to $10.35 billion from $10.71 billion. Analysts polled by FactSet expected $10.15 billion.
"We had a great start to the year, driven by our proven growth strategy and the impact of our PPI Business System," said Chief Executive Marc Casper.
Thermo Fisher Scientific raised its 2024 guidance which it said reflected stronger operational performance. It forecast revenue between $42.3 billion and $43.3 billion as well as adjusted earnings per-share in the range of $21.14 a share and $22.02 a share.
It previously guided for revenue between $42.1 billion and $43.3 billion as well as adjusted earnings per-share in the range of $20.95 a share and $22 a share.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 24, 2024 06:37 ET (10:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom